Clinical Trial

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-23; most recent amendment 2024-01-24.
Status change: Withdrawn → Recruiting 2024-01-24
Status change: Recruiting → Withdrawn 2024-01-08
Status change: Not Yet Recruiting → Recruiting 2023-05-16
Trial Details
NCT Number NCT05746897
Lead Sponsor Hefei TG ImmunoPharma Co., Ltd.
Conditions Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Enrollment 38 participants
Start Date 2023-04-13
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-01-26